Phase II study of alemtuzumab–rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes

References

• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
   PubMed Web of Science ®Google Scholar
• Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98:1326–1331.
   PubMed Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115–3120.
   PubMed Web of Science ®Google Scholar
• Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004;83:634–645.
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768–773.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Chen YH, Peterson LC, Dittmann D, et al. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. Am J Clin Pathol 2007;127:182–191.
   PubMed Web of Science ®Google Scholar
• Monaghan SA, Peterson LC, James C, et al. Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL). Cytometry B Clin Cytom 2003;56:30–42.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378–4384.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885–891.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30:3209–3216.
   PubMed Web of Science ®Google Scholar
• Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012;30:980–988.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008;113:2110–2118.
   PubMed Web of Science ®Google Scholar
• Karlsson C, Norin S, Kimby E, et al. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 2006;20:2204–2207.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63:803–843.
   PubMed Web of Science ®Google Scholar
• Tuthill M, Crook T, Corbet T, et al. Rapid infusion of rituximab over 60 min. Eur J Haematol 2009;82:322–325.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999;17:791–795.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008;111:1816–1819.
   PubMed Web of Science ®Google Scholar
• Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010;116:4771–4776.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230–239.
   PubMed Web of Science ®Google Scholar
• Engelfriet CP, Overbeeke MA, von dem Borne AE. Autoimmune hemolytic anemia. Semin Hematol 1992;29:3–12.
   PubMed Web of Science ®Google Scholar
• Kyasa MJ, Parrish RS, Schichman SA, et al. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003;74:1–8.
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95:2786–2792.
   PubMed Web of Science ®Google Scholar
• Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008;141:615–621.
   PubMed Web of Science ®Google Scholar
• Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008;111:1110–1116.
   PubMed Web of Science ®Google Scholar
• Reda G, Maura F, Gritti G, et al. Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. Am J Hematol 2012;87:936–937.
   PubMed Web of Science ®Google Scholar
• Fan L, Wang L, Zhang R, et al. Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:1749–1756.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008;142:202–215.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Keating MJ, Wierda WG. Richter's transformation in chronic lymphocytic leukemia. Curr Rhematol Malig Rep 2007;2:265–271.
   PubMedGoogle Scholar
• Parikh SA, Rabe KG, Call TG, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol 2013;162:774–782.
   PubMed Web of Science ®Google Scholar
• Flynn JM, Andritsos L, Lucas D, et al. Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus. Br J Haematol 2010;149:388–390.
   PubMed Web of Science ®Google Scholar
• Schollkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 2007;121:151–156.
   PubMed Web of Science ®Google Scholar
• Quaglino D, Di Leonardo G, Lalli G, et al. Association between chronic lymphocytic leukaemia and secondary tumours: unusual occurrence of a neuroendocrine (Merkell cell) carcinoma. Eur Rev Med Pharmacol Sci 1997;1:11–16.
   PubMedGoogle Scholar
• Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975;232:267–269.
   PubMed Web of Science ®Google Scholar
• Beiggi S, Johnston JB, Seftel MD, et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer 2013;109:1287–1290.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Gemei M, Luciano L, et al. Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?J Clin Oncol 2012;30:e327–e330.
   PubMed Web of Science ®Google Scholar
• Buda-Okreglak EM, Cordaro DV. Simultaneous chronic myeloid leukemia and chronic lymphocytic leukemia. Blood 2011; 117:5279.
   PubMed Web of Science ®Google Scholar
• Alley CL, Wang E, Dunphy CH, et al. Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature. Arch Pathol Lab Med 2013;137:503–517.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002;20:3878–3884.
   PubMed Web of Science ®Google Scholar
• Smith MR, Neuberg D, Flinn IW, et al. Incidence of therapy- related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood 2011; 118:3525–3527.
   PubMed Web of Science ®Google Scholar